The free-to-attend virtual event will consist of four educational parts:
1. Case presentations from clinicians
2. Live Q&A session
3. QIAGEN solution showcase
4. Future outlook on precision oncology
As the role of the Molecular Tumor Board (MTB) becomes increasingly important in the implementation of evidence-based precision cancer medicine programs, molecular pathology labs must overcome challenges in genomic test interpretation to ensure maximum clinical utility of molecular profiling results.
At the Clinician's Roundtable 2024, hear from clinicians at leading universities and organizations as they present real-world case studies of how molecular pathology labs can improve test turnaround, standardize test interpretation, and deliver comprehensive genomic reports with personalized diagnostic, prognostic, and therapeutic information for each patient.
David A. Barbie, MD
Director, Lowe Center for Thoracic Oncology
Associate Director, Belfer Center for Applied Cancer Research Physician
Associate Professor of Medicine, Harvard Medical School
Andrew A. Lane, MD, PhD
Director, Blastic Plasmacytoid Dendritic Cell Neoplasm Center
Associate Professor of Medicine, Harvard Medical School Physician
Dr. Kathryn Bungartz, PhD
Chief Scientific Officer,
QIAGEN Digital Insights
Iman Bhattacharya, MS
Senior Global Product Marketing Manager, QIAGEN Digital Insights
Agnostic variant interpretation and reporting platform for precision oncology testing
Agnostic cloud-based software-as-a-service (SaaS) solution for precision oncology testing
Expert-curated databases to enrich existing pipelines and support MTB recommendations
The 2024 Clinician's Roundtable is a unique event for molecular pathology labs to learn from the experiences of clinicians at leading cancer institutes and learn about variant interpretation and reporting solutions to advance your precision oncology program.
